Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma

NIAID Data Ecosystem2026-03-11 收录

胶质母细胞瘤

癌症干细胞靶点验证

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110869 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

创建时间：

2019-10-14

Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype - mouse RNAseq experiments

胶质母细胞瘤

表观遗传调控

Glioblastomas in adult patients are classified into four subtypes, IDH, MES, RTK I, and RTK II, based on DNA-methylation and RNA-expression data. Tumour subtype transitions are common during treatment

NIAID Data Ecosystem60

Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR

胶质母细胞瘤

信号传导

An in-frame deletion mutation in Epidermal Growth Receptor (EGFR), ΔEGFR is a common and potent oncogene in glioblastoma (GBM), promoting growth and survival of cancer cells. This mutated receptor is

NIAID Data Ecosystem40

DataSheet_1_BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?.docx

胶质母细胞瘤

BRAF抑制

IDH-wild type (wt) glioblastoma (GB) accounts for approximately 90% of all GB and has a poor outcome. Surgery and adjuvant therapy with temozolomide and radiotherapy is the main therapeutic approach.

NIAID Data Ecosystem30

Table_5_A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.xlsx

胶质母细胞瘤

DNA甲基化

Glioblastoma (GBM) is the most malignant glioma, with a median overall survival (OS) of 14–16 months. Temozolomide (TMZ) is the first-line chemotherapy drug for glioma, but whether TMZ should be withh

NIAID Data Ecosystem50

Table_1_Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions.docx

胶质母细胞瘤

自然杀伤细胞

Glioblastoma (GBM) is the most aggressive brain malignancy in adults, where survival is approximately 14.6 months. Novel therapies are urgently needed and immunotherapy has hailed a new dawn for treat

NIAID Data Ecosystem40

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma

资源简介：

相关数据集